In this study, CEBPA, RUNX1, BCORL1, and NF1 variants detected in young AML patients and WT1, KRAS, and JAK2 variants detected in elderly AML patients were consistent with the literature in diagnosis and risk stratification and disease follow-up. This evidence concerns the gene KRAS and acute myeloid leukemia.